Form 8-K - Current report:
SEC Accession No. 0001437749-22-006835
Filing Date
2022-03-21
Accepted
2022-03-21 16:26:57
Documents
15
Period of Report
2022-03-21
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20220321_8k.htm   iXBRL 8-K 30404
2 EXHIBIT 99.1 ex_349292.htm EX-99.1 22142
7 image2.jpg GRAPHIC 8024
  Complete submission text file 0001437749-22-006835.txt   204236

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dffn-20220321.xsd EX-101.SCH 3601
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20220321_def.xml EX-101.DEF 11532
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20220321_lab.xml EX-101.LAB 15414
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20220321_pre.xml EX-101.PRE 11688
9 EXTRACTED XBRL INSTANCE DOCUMENT dffn20220321_8k_htm.xml XML 2578
Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

EIN.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 22755989
SIC: 2834 Pharmaceutical Preparations